Drug Profile
Research programme: antibacterial and antifungal therapeutics - Sealife Pharma
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Sealife Pharma
- Class Antibacterials; Antifungals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gram-negative infections; Gram-positive infections; Mycoses
Most Recent Events
- 06 Sep 2023 Antibacterial and antifungal therapeutics is still in preclinical trials for Gram-negative infections, Gram-positive infections and Mycoses in Austria (Sealife Pharma pipeline, September 2023)
- 14 Jun 2016 Pharmacokinetics and pharmacodynamics data from preclinical trial in Gram positive bacterial infections, Gram negative bacterial infections and Mycoses released by Sealife Pharma
- 13 Jun 2016 Preclinical trials in Gram-negative infections in Austria (unspecified route) before June 2016